Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Methods × Endocrine × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 23 Gastrointestinal 18 Thoracic 13 Gynecologic 13 Genitourinary 10 Tumor-Agnostic 8 Other hematologic neoplasm 8 Other 7 Lymphoid 7 Other solid neoplasm 5 Dermatologic 5 Sarcoma 4 Head & Neck 4 Other neoplasm 2 CNS 2 Plasma cell 1 Myeloid 1 Endocrine 1

Conditions

Neoplasms 1 Carcinoma, Neuroendocrine 1

Interventions

Everolimus 28 Octreotide 13 Cisplatin 12 Sunitinib 10 Etoposide 9 Doxorubicin 8 pembrolizumab 7 pasireotide 7 lutetium Lu 177 dotatate 7 lanreotide 7 Temozolomide 7 3-Iodobenzylguanidine 7 gallium Ga 68 dotatate 6 Positron Emission Tomography Computed Tomography 6 Magnetic Resonance Spectroscopy 6 Bevacizumab 6 pazopanib 5 Surgical Procedures, Operative 5 Radiotherapy 5 Paclitaxel 5 Irinotecan 5 Fulvestrant 5 surufatinib 4 lenvatinib 4 avelumab 4 Sorafenib 4 Radiosurgery 4 Mitotane 4 Iodine-131 4 Gefitinib 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04478175 2022-11-17

DParcoursDig

Institut Curie

Phase NA Completed

Neoplasms, Carcinoma, Neuroendocrine

Data powered by HemOnc (CC BY 4.0) Colophon ⚡